Hikma Pharmaceuticals Plc Transaction in Own Shares (0361N)
September 02 2013 - 10:06AM
UK Regulatory
TIDMHIK
RNS Number : 0361N
Hikma Pharmaceuticals Plc
02 September 2013
Hikma Pharmaceuticals PLC
Transaction in Own Shares
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (the
"Company") announces that on 30 August 2013 it purchased 35,000 of
its ordinary shares of GBP0.10 each at an average price of
GBP10.147 per share (the "Share Buy-Back").
The highest price paid for a share was GBP10.14 and the lowest
price paid for a share was GBP10.15.
The shares purchased pursuant to the Share Buy-Back will be held
as treasury shares.
Following the Share Buy-Back the Company holds a total of
210,000 ordinary shares of GBP0.10 each as treasury shares and has
197,731,128 ordinary shares of GBP0.10 each in issue (excluding
those shares held as treasury shares).
Any shares purchased under the Share Buy-back will count towards
the Company's general buy-back authority of approximately 10% of
the Company's issued share capital (aggregate nominal amount equal
to GBP1,974,844), as approved at the Company's Annual General
Meeting on 16 May 2013.
The total number of voting rights in the Company, excluding
treasury shares, as at 30 August 2013 is 197,731,128. This figure
may be used by shareholders as the denominator for the calculations
by which they can determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the Financial Conduct Authority's Disclosure and Transparency
Rules.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
=========================== =================
Peter Speirs
Company Secretary +44 20 7399 2760
=========================== =================
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2012, Hikma achieved
revenues of $1,108.7 million and profit attributable to
shareholders of $100.3 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
POSZLLFBXKFBBBX
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024